EA201892386A1 - Химерные нейротоксины - Google Patents

Химерные нейротоксины

Info

Publication number
EA201892386A1
EA201892386A1 EA201892386A EA201892386A EA201892386A1 EA 201892386 A1 EA201892386 A1 EA 201892386A1 EA 201892386 A EA201892386 A EA 201892386A EA 201892386 A EA201892386 A EA 201892386A EA 201892386 A1 EA201892386 A1 EA 201892386A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chimeric neurotoxins
neurotoxins
chimeric
therapy
relates
Prior art date
Application number
EA201892386A
Other languages
English (en)
Inventor
Сай Ман Лю
Original Assignee
Ипсен Биофарм Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Биофарм Лимитед filed Critical Ипсен Биофарм Лимитед
Publication of EA201892386A1 publication Critical patent/EA201892386A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)

Abstract

Настоящее изобретение относится к химерным нейротоксинам с улучшенными свойствами и к их применению в терапии.
EA201892386A 2016-05-05 2017-05-05 Химерные нейротоксины EA201892386A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1607901.4A GB201607901D0 (en) 2016-05-05 2016-05-05 Chimeric neurotoxins
PCT/EP2017/060821 WO2017191315A1 (en) 2016-05-05 2017-05-05 Chimeric neurotoxins

Publications (1)

Publication Number Publication Date
EA201892386A1 true EA201892386A1 (ru) 2019-04-30

Family

ID=56297235

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892386A EA201892386A1 (ru) 2016-05-05 2017-05-05 Химерные нейротоксины

Country Status (23)

Country Link
US (2) US11434265B2 (ru)
EP (2) EP3889168A1 (ru)
JP (3) JP7421862B2 (ru)
KR (2) KR20240033165A (ru)
CN (2) CN116333158A (ru)
AR (1) AR108689A1 (ru)
AU (3) AU2017260389B2 (ru)
BR (1) BR112018072587A2 (ru)
CA (1) CA3020640A1 (ru)
DK (1) DK3452071T3 (ru)
EA (1) EA201892386A1 (ru)
ES (1) ES2866899T3 (ru)
GB (1) GB201607901D0 (ru)
HU (1) HUE054856T2 (ru)
IL (1) IL262575B (ru)
MX (1) MX2018013141A (ru)
PL (1) PL3452071T3 (ru)
PT (1) PT3452071T (ru)
SA (1) SA518400335B1 (ru)
SG (1) SG11201809064QA (ru)
TW (3) TW202415674A (ru)
UA (1) UA126563C2 (ru)
WO (1) WO2017191315A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3372239T3 (da) 2012-05-30 2021-02-01 Harvard College Manipuleret botulinumneurotoksin
BR112015003591B1 (pt) * 2012-11-21 2022-02-01 Ipsen Bioinnovation Limited Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
EP3274364B1 (en) * 2015-03-26 2021-08-04 President and Fellows of Harvard College Engineered botulinum neurotoxin
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
SG11201810210UA (en) * 2016-06-08 2018-12-28 Childrens Medical Center Engineered botulinum neurotoxins
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2019067815A2 (en) 2017-09-29 2019-04-04 Children's Medical Center Corporation NEUROTOXIN-LIKE TOXIN AND USES THEREOF
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
EP3775046A1 (en) * 2018-04-06 2021-02-17 Dupont Polymers, Inc. Additive manufacturing compositions
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
EP3753568A1 (en) 2019-06-21 2020-12-23 Fastox Pharma SA Composition modulating botulinum neurotoxin effect
GB201914034D0 (en) * 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
TWI825396B (zh) 2020-03-16 2023-12-11 英商艾普森生物製藥有限公司 肢體痙攣之治療
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
JP2024534384A (ja) 2021-09-16 2024-09-20 イプセン バイオファーム リミテッド 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ
EP4404955A1 (en) 2021-09-23 2024-07-31 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
KR20240116485A (ko) 2021-11-22 2024-07-29 입센 바이오팜 리미티드 통증의 치료
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000066I2 (de) 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5714469A (en) 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
CA2501856A1 (en) 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US7465457B2 (en) * 2005-04-14 2008-12-16 Wisconsin Alumni Research Foundation Method for preparing botulinum neurotoxin type A light chain
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
BRPI0916964A2 (pt) * 2008-08-29 2015-11-24 Merz Pharma Gmbh & Co Kgaa polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
WO2010120766A1 (en) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
EP2650003B1 (en) * 2010-05-20 2016-07-27 Allergan, Inc. Degradable clostridial toxins
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2013102088A2 (en) * 2011-12-31 2013-07-04 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
DK3372239T3 (da) * 2012-05-30 2021-02-01 Harvard College Manipuleret botulinumneurotoksin
BR112015003591B1 (pt) * 2012-11-21 2022-02-01 Ipsen Bioinnovation Limited Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US10647750B2 (en) * 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
EP3274364B1 (en) * 2015-03-26 2021-08-04 President and Fellows of Harvard College Engineered botulinum neurotoxin
JP2018530315A (ja) * 2015-08-27 2018-10-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 疼痛の治療を目的とする組成物及び方法
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
SG11201810210UA (en) * 2016-06-08 2018-12-28 Childrens Medical Center Engineered botulinum neurotoxins
HUE061429T2 (hu) * 2016-07-08 2023-06-28 Childrens Medical Center Új botulinum neurotoxin és származékai
US11117935B2 (en) * 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3600384A1 (en) * 2017-03-24 2020-02-05 Merz Pharma GmbH & Co. KGaA Improved use of botulinum neurotoxin in the treatment of sialorrhea
US10329543B2 (en) * 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
KR20200115584A (ko) * 2018-01-30 2020-10-07 칠드런'즈 메디컬 센터 코포레이션 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산
US10786438B2 (en) * 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications

Also Published As

Publication number Publication date
CA3020640A1 (en) 2017-11-09
AU2017260389A1 (en) 2018-11-22
EP3452071A1 (en) 2019-03-13
PT3452071T (pt) 2021-05-31
CN116333158A (zh) 2023-06-27
HUE054856T2 (hu) 2021-10-28
TWI751157B (zh) 2022-01-01
WO2017191315A1 (en) 2017-11-09
IL262575B (en) 2022-01-01
TW202415674A (zh) 2024-04-16
JP2019520799A (ja) 2019-07-25
DK3452071T3 (da) 2021-06-07
AU2017260389B2 (en) 2021-09-23
CN109069576B (zh) 2022-06-10
SG11201809064QA (en) 2018-11-29
AU2021266312B2 (en) 2024-01-11
UA126563C2 (uk) 2022-11-02
TW201808986A (zh) 2018-03-16
CN109069576A (zh) 2018-12-21
JP2024010008A (ja) 2024-01-23
BR112018072587A2 (pt) 2019-02-19
GB201607901D0 (en) 2016-06-22
TWI832162B (zh) 2024-02-11
EP3889168A1 (en) 2021-10-06
TW202237627A (zh) 2022-10-01
ES2866899T3 (es) 2021-10-20
KR20190003698A (ko) 2019-01-09
US20230025090A1 (en) 2023-01-26
KR102643970B1 (ko) 2024-03-11
MX2018013141A (es) 2019-02-21
AR108689A1 (es) 2018-09-19
AU2024202302A1 (en) 2024-06-13
PL3452071T3 (pl) 2021-10-25
EP3452071B1 (en) 2021-04-07
KR20240033165A (ko) 2024-03-12
AU2021266312A1 (en) 2021-12-09
US11434265B2 (en) 2022-09-06
JP2022105100A (ja) 2022-07-12
JP7421862B2 (ja) 2024-01-25
US20190127427A1 (en) 2019-05-02
SA518400335B1 (ar) 2023-01-31

Similar Documents

Publication Publication Date Title
EA201892386A1 (ru) Химерные нейротоксины
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2016002123A1 (es) Nuevo polisacárido y usos del mismo
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
BR112017006664A2 (pt) terapias de combinação
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
EA201690314A1 (ru) Анти-garp-белок и его применения
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
AU201612434S (en) Chair
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
AU361329S (en) Footstool
AU359433S (en) Cleaner
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp